openPR Logo
Press release

Invitation from Roderick E. Hubbard at Vernalis Research chairing SMi’s Drug Discovery Conference

01-17-2019 04:02 PM CET | Health & Medicine

Press release from: SMi Group

drug discovery chemistry, admet, chemistry, small molecules, drug discovery process, R&D pipeline

drug discovery chemistry, admet, chemistry, small molecules, drug discovery process, R&D pipeline

SMi reports: Conference Chairman Roderick E. Hubbard from Vernalis personally invites you The 3rd Annual Drug Discovery Chemistry Conference, which is proudly sponsored by Selvita.

The two-day conference is returning to London, UK this year on the 18th and 19th March and aims to look beyond to the next generation of enabling tools and technologies enabling a more rational, fast and successful drug discovery.

Roderick E. Hubbard; Professor, University of York and Senior Fellow, Vernalis Research. Vernalis Research is based in Cambridge in the UK that focuses on developing and applying fragment and structure-based methods to solve problems in drug discovery.
Professor Hubbard has been an academic at York for over 35 years working with methods for analysis and exploitation of protein structure. Since 2001 he has split his time between Vernalis and York (fragment methods for chemical biology and industrial biotechnology). In addition, he works with UK Research Councils and consults with pharmaceutical and technology companies around the world.

On his personal invitation he mentions:
“The drug discovery field continues to undergo rapid change in response to the increased pressures of developing new therapies, reducing costs and avoiding late stage drug failure. As an industry, we continue to look for innovative methods to provide access to new target classes and to speed up and improve the drug discovery process. Although these new methods always sound compelling, it always takes some time and experience to realise their potential.

This Drug Discovery Chemistry Conference will feature presentations from scientists with expertise in many of the emerging methods and disciplines:
• Opportunities and applications for AI across the drug discovery process
• Hit ID –encoded libraries, fragments, PROTACs, macrocycles, antibodies
• Optimising the process and enabling drug discovery for challenging targets

PLUS you can also attend the post-conference workshop (20th March 2019) on Artificial Intelligence in Drug Discovery, which is led by Dr Nick Camp, Drug Discovery Consultant at Nick Camp Consulting Ltd

You can visit the website and download the brochure from the website at: http://www.drug-discovery.co.uk/PR3

Should you wish to join us the conference and/or workshop, you can register your place at http://www.drug-discovery.co.uk/PR3 and save £100 expires this month.

For sponsorship opportunities please contact Alia Malick, Director on +44 (0) 20 7827 6168 or email amalick@smi-online.co.uk.

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

Drug Discovery Chemistry
Conference: 18th & 19th March 2019
Half-day post-conference workshop: 20th March 2019 - 8:30am to 12:30pm
Copthorne Tara Hotel, London, UK
http://www.drug-discovery.co.uk/PR3

Follow us @SMiPharm on Twitter
#SMiDrugDischem

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Marketing Dept, 1st Floor
1 Westminster Bridge Road

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Invitation from Roderick E. Hubbard at Vernalis Research chairing SMi’s Drug Discovery Conference here

News-ID: 1509257 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase